Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

Abstract Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE). We...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sheriza Baksh, Jiajun Wen, Omar Mansour, Hsien-Yen Chang, Mara McAdams-DeMarco, Jodi B. Segal, Stephan Ehrhardt, G. Caleb Alexander
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/a638a7a3df1f45569c97db45d9e14c45
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires